Tourmaline Bio, Inc.
Tourmaline Bio, Inc. (TRML) Revenue
Annual & quarterly revenue history · segment & region breakdown
TRML · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsTourmaline Bio, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2024.
Revenue trend
2024 – 2019 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2024-12-31 | $0.00B | +$0.00B | — |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | — | — |
Compare revenue vs peers
BiotechnologyCompare TRML revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Tourmaline Bio, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Tourmaline Bio, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Tourmaline Bio, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
TRML revenue · 4 questionsTRML's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2024.
▸ Source: FMP · Tourmaline Bio, Inc. SEC filings · GAAP · Tourmaline Bio, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026